Page last updated: 2024-09-05

l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine and Atherosclerotic Parkinsonism

l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine has been researched along with Atherosclerotic Parkinsonism in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Foster, AC; Hill, RG; Iversen, L; Iversen, SD; Kemp, JA; Leeson, PD; Rupniak, NM; Saywell, K; Tricklebank, MD; Williams, BJ1
Iversen, SD; Miyaji, M; Naruse, T; Rupniak, NM; Tye, SJ1

Reviews

1 review(s) available for l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine and Atherosclerotic Parkinsonism

ArticleYear
Neurotoxin-related research: from the laboratory to the clinic.
    Annals of the New York Academy of Sciences, 1992, May-11, Volume: 648

    Topics: Animals; Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Mice; MPTP Poisoning; Nervous System; Neurotoxins; Oxazines; Parkinson Disease, Secondary; Prodrugs; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Saimiri

1992

Other Studies

1 other study(ies) available for l-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine and Atherosclerotic Parkinsonism

ArticleYear
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
    Clinical neuropharmacology, 1989, Volume: 12, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinson Disease, Secondary; Prodrugs; Saimiri; Time Factors

1989